missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ JNJ 1013

Click to view available options
Quantity:
5 mg
Unit Size:
5mg
Description
JNJ 1013 is a potent interleukin 1 receptor associated kinase 1 (IRAK1) PROTAC™ Degrader (DC50 = 3 nM; Dmax = 96%). In ABC DLBCL cell lines with MyD88 L265P mutation, JNJ 1013 potently inhibits IRAK1 downstream signaling pathways, induces apoptosis, and shows strong anti-proliferative effects. PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
Spécification
Spécification
| Chemical Name or Material | N-(4-(4-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)-2-methoxyphenyl)-6-(1H-pyrazol-5-yl)picolinamide |
| CAS | 2597343-08-1 |
| Quantity | 5 mg |
| Target | Active Degraders |
| Molecular Formula | C46H55N9O7S |
| Purity | 98% |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu